Dose-escalation study of pemetrexed in combination with carboplatin followed by pemetrexed maintenance therapy for advanced non-small cell lung cancer

作者：Okamoto Isamu^*; Takeda Koji; Daga Haruko; Miyazaki Masaki; Yonesaka Kimio; Kiyota Hidemi; Tsurutani Junji; Ueda Shinya; Ichikawa Yasuko; Takeda Masayuki; Sekiguchi Risa; Tominaga Kiyomi; Enatsu Sotaro; Nambu Yoshihiro; Nakagawa Kazuhiko

来源：Lung Cancer, 2010, 70(2): 168-173.

DOI：10.1016/j.lungcan.2010.02.007

• Pemetrexed
• Carboplatin
• Dose-escalation
• First-line therapy
• Maintenance therapy
• NSCLC

Introduction: The primary objectives of this study were to determine the recommended dose of pemetrexed and carboplatin in patients with chemo-naive advanced non-small cell lung cancer (NSCLC).
Methods: Patients received escalated doses of carboplatin area under the concentration-time curve (AUC) of 5 (cohort 1) or 6 (cohort 2) and pemetrexed 500 mg/m(2) every 3 weeks for six cycles. For patients with objective response and stable disease, pemetrexed were continued until disease progression or unacceptable toxicity.
Results: In cohort 1, a dose-limiting toxicity (DLT) was observed in one of the six patients: grade 4 thrombocytopenia. No DLTs were seen in the first 6 patients of cohort 2, and thus the combination of pemetrexed 500 mg/m2 plus carboplatin at AUC 6 was determined as the recommended dose. Among a total of 20 patients, 8 patients received a median of four cycles of pemetrexed monotherapy in a maintenance setting without unexpected or cumulative toxicities. No complete responses and 12 partial responses were observed, giving an overall response rate of 60.0% [95% confidence interval (CI), 36.1-80.9%]. Median progression-free survival time for all patients was 7.6 months (95% CI: 4.8-8.0 months).
Conclusions: Pemetrexed 500 mg/m(2) plus carboplatin AUC 6 combination therapy followed by pemetrexed maintenance therapy, is generally tolerable, and shows encouraging antitumor activity in chemotherapy-naive patients with advanced NSCLC.

• 出版日期2010-11